Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.91 (market cap $3.69B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2× iShares MSCI United Kingdom (FTSE)'s market cap, and iShares MSCI United Kingdom (FTSE) is more actively traded (701,016 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 48 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EWU | SYRE | |
|---|---|---|
Market Cap | $3.69B | $7.52B |
Volume | 701,016 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $108.92 |
52-Week Low | $41.34 | $22.18 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.82 with a modest 0.26% daily gain, though technical indicators signal a bearish trend with moving averages and overall momentum pointing downward. The stock faces headwinds from UK economic concerns including rising gilt yields and inflation pressures. Recent news highlights sector-specific volatility in UK banking and housing markets, creating a challenging environment for this UK-focused ETF.
The outlook remains cautious given macroeconomic pressures on UK assets. Investment opportunity exists for contrarian investors betting on UK recovery, but risks include persistent inflation, rising interest rates, and political uncertainty around upcoming budget decisions that could impact financial and housing sectors significantly.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
